Compare GGAL & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GGAL | BLTE |
|---|---|---|
| Founded | 1905 | 2018 |
| Country | Argentina | United States |
| Employees | 10079 | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 6.2B |
| IPO Year | N/A | 2021 |
| Metric | GGAL | BLTE |
|---|---|---|
| Price | $53.21 | $146.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $69.00 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 1.6M | 231.7K |
| Earning Date | 03-07-2023 | 05-08-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $62.29 | N/A |
| Revenue Next Year | $22.88 | $492.11 |
| P/E Ratio | $13.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.89 | $56.68 |
| 52 Week High | $62.11 | $200.00 |
| Indicator | GGAL | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 59.18 | 53.71 |
| Support Level | $47.43 | $148.00 |
| Resistance Level | $56.17 | $151.41 |
| Average True Range (ATR) | 2.24 | 7.89 |
| MACD | 0.38 | 1.61 |
| Stochastic Oscillator | 56.69 | 85.97 |
Grupo Financiero Galicia SA is a financial service holding company. It provides general banking services, proprietary brand credit card services, personal loans, insurance, and other services. The company's operating business segments are Banks, Ecosistema Naranja X, Insurance, Adjustments, and Other Businesses. The company generates maximum revenue from Banks. Geographically its operate in Argentina, Uruguay, and the majority of its revenue comes from Argentina.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.